Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H773

UPID:
DCTP1_HUMAN

ALTERNATIVE NAMES:
Deoxycytidine-triphosphatase 1; RS21C6; XTP3-transactivated gene A protein

ALTERNATIVE UPACC:
Q9H773

BACKGROUND:
The enzyme dCTP pyrophosphatase 1, recognized by alternative names such as RS21C6 and XTP3-transactivated gene A protein, is pivotal in the catabolism of dNTPs to nucleoside monophosphates. It prioritizes dCTP and similar analogs, potentially offering higher efficiency for these substrates. This activity is essential for the prevention of genotoxic nucleotide analog incorporation, thereby protecting DNA and RNA.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of dCTP pyrophosphatase 1 holds promise for the development of novel therapeutic approaches. Its crucial role in maintaining genomic stability by metabolizing potentially harmful nucleotide analogs underscores its therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.